1. Introduction
===============

Targeting protein for Xklp2 (TPX2) is a proliferation-related protein first described by Heidebrecht et al,^\[[@R1]\]^ who found a nuclear antigen roughly 100 kDa molecular mass exclusively expressed in S, M, and G2 phases, and named p100 at that time. Before long, Vernos' group discovered that this novel cell cycle--related protein played an essential role in the localization of GST-Xklp2-tail to microtubule (MT) minus ends.^\[[@R2]\]^ Further studies indicated that TPX2 controlled MT nucleation, function, and coaction with other cell structures as an MT-associated protein (MAP), and improper expression of TPX2 lead to chromosomal instability, caused centrosome amplification, and developed aneuploidy, which highly correlated with the occurrences and developments of various tumors.^\[[@R3]--[@R6]\]^ More recently, researchers found TPX2 promoted the proliferation and migration of tumor cells by regulating Aurora-polo-like kinase 1 (PLK1) cascades, which worked as key signaling modules in mitosis.^\[[@R7],[@R8]\]^ As a result, TPX2/Aurora-PLK1 signaling might be a potential therapeutic target in malignant tumors.^\[[@R9]\]^ Huang et al^\[[@R10]\]^ reported TPX2 silencing mediated by the joint action of microvesicles and ultrasonic radiation significantly inhibited the progression of SKOV3 cells, indicating an effective gene therapy against ovarian cancer.

Several research groups have paid special attention to the relationship between TPX2 expression and various human tumors, strong research evidence revealed that in most human cancers, such as lung,^\[[@R11]\]^ hepatic,^\[[@R12]\]^ colon,^\[[@R13]\]^ pancreatic,^\[[@R14]\]^ salivary gland,^\[[@R15]\]^ breast,^\[[@R16]\]^ and cervical cancers,^\[[@R17],[@R18]\]^ TPX2 proved to be highly expressed. However, the prognostic value of the TPX2 expression in various solid tumors is still controversial.

Independent studies showed that in most cases overexpression of TPX2 had a negative impact on the prognosis of various types of solid tumors, such as astrocytoma,^\[[@R19]\]^ ovarian cancer,^\[[@R20]\]^ renal cell cancer,^\[[@R21]\]^ gastric cancer,^\[[@R22]--[@R24]\]^ bladder cancer,^\[[@R25]\]^ esophageal squamous cell cancer,^\[[@R26]\]^ hepatocellular cancer,^\[[@R12],[@R27]\]^ colon cancer,^\[[@R28]\]^ and lung cancer.^\[[@R29]\]^ However, Pan et al^\[[@R30]\]^ found that the expression of TPX2 in tumor tissues of patients with prostate cancer was not related to their survival time.

Therefore, to clarify a better understanding of the prognostic significance of TPX2 overexpression in human solid tumors, we performed a meta-analysis combining 13 studies (2134 patients) as well as subgroups analysis, aiming to assess the correlation of elevated TPX2 expression with survival in solid tumors, and to learn a bit more about the clinical role of TPX2 as a therapeutic target and prognostic biomarker for solid tumors.

2. Methods
==========

This meta-analysis was performed based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.^\[[@R31]\]^ This study is a summary and analysis of previous published studies, so there is no need for ethical approval.

2.1. Identification and selection of studies
--------------------------------------------

We searched 3 different online databases, EBSCO, PubMed, and Web of Science, for studies that evaluated the relationship between TPX2 expression and survival in solid tumors until December 2017. The search terms included "Targeting protein for Xklp2" or "TPX2" or "DIL-2" or "C20orf2" and "neoplasms," the search results were limited to the studies of human solid tumors. No publication time and language restrictions were imposed. Of the 3 databases, we identified 97, 85, and 204 items, respectively. The inclusion criteria were the literatures provided overall survival (OS) data or disease-free survival (DFS) data or both of them, follow-up time at least 3 years and writing in English. We manually filtered the retrieved articles to guarantee the sensitivity of the search strategy. Inter-rater reliability was evaluated by Cohen kappa coefficient. If there were disagreements, resolved through consensus.

2.2. Endpoints of interest
--------------------------

The primary endpoints were 3- or 5-year OS or DFS. Patients were assigned to control or experimental arms according to the TPX2 expression cut-off values defined by individual studies.

2.3. Data extraction
--------------------

Two authors (SW and YC) independently reviewed the articles and extracted information using predesigned data form, which contained the publication time and first author of article, country of origin, tumor type, number of patients, age, histological type and stage, follow-up time, cut-off to determine TPX2 positivity, number of TPX2 positive patients and controls, detection method, and outcome endpoint. Survival data were extracted from texts, tables, or Kaplan-Meier curves for both control (negative or low TPX2 expression) and experimental (positive or high TPX2 expression) arms. Some articles only provided Kaplan-Meier curves, in these cases, we extracted data points using Engauge Digitizer 10.4. For the studies included in our meta-analysis were all retrospective cohort studies, we assessed research quality by Newcastle-Ottawa Scale (NOS).^\[[@R32],[@R33]\]^ Researches with scores \>6 points were considered to be high-quality researches.

2.4. Statistical analysis
-------------------------

The relative frequency of OS or DFS at 3 and 5 years between control and experimental arms was presented as an odds ratio (OR) with 95% confidence interval (CI) calculated by the application of Mantel-Haenszel random effect model. And the pooled ORs were estimated by *Z* test. Cochran *Q* and *I*^2^ statistics were used to assess the heterogeneity. Subgroup analysis and sensitivity analysis were performed to explore the potential sources of heterogeneity. Sensitivity analyses were carried out for different detection methods and NOS scores of included studies. Subgroup analysis was performed on adequately sized subgroups (containing 2 researches or more). Publication bias was assessed by visual inspection of the funnel plot. All statistical analyses were performed using RevMan 5.3 analysis software (Cochrane Collaboration, Copenhagen, Denmark). All statistical tests were 2-tailed, and statistical significance was defined as *P* ≤ .05.

3. Results
==========

3.1. Search results and study characteristics
---------------------------------------------

A total of 386 records were retrieved from 3 databases by the initial search. After carefully reviewing, 13 studies with 2134 patients were finally included in our meta-analysis (Fig. [1](#F1){ref-type="fig"}). Characteristics of studies with OS or DFS data are presented in Table [1](#T1){ref-type="table"}. Of these studies, 3 evaluated gastric cancer,^\[[@R22]--[@R24]\]^ 2 evaluated hepatocellular cancer,^\[[@R12],[@R27]\]^ and 1 each evaluated malignant astrocytoma,^\[[@R19]\]^ prostate cancer,^\[[@R30]\]^ epithelial ovarian cancer,^\[[@R20]\]^ bladder carcinoma,^\[[@R25]\]^ colon cancer,^\[[@R28]\]^ esophageal squamous cell cancer,^\[[@R26]\]^ renal cell cancer,^\[[@R21]\]^ and squamous cell lung carcinoma.^\[[@R29]\]^ The quality scores of included studies varied from 5 to 9. Ten of 13 studies scored \>6 points and considered to be high-quality researches (see Table, Supplemental Content, which illustrates the quality scores of enrolled studies by Newcastle-Ottawa Quality Assessment).

![Flow diagram of the meta-analysis process. DFS = disease-free survival, OS = overall survival.](medi-97-e13018-g001){#F1}
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Characteristics of studies included in the meta-analysis.
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3.2. Evaluation and expression of TPX2
--------------------------------------

Table [2](#T2){ref-type="table"} presents the TPX2 detection methods and cut-off values for TPX2 overexpression defined in the individual studies. Eleven investigations detected the TPX2 status by immunohistochemistry (IHC), 1 study used RNA-Sequencing, and the remaining 1 research used 2 detection methods, IHC, and cDNA microarray, respectively. For the IHC method, the cut-off points for TPX2 positive or high expression according to the combination of masculine cells proportion and the staining intensity.

###### 

Evaluation of human targeting protein for Xklp2 by different detection method in the selected studies.
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3.3. Association of TPX2 with survival
--------------------------------------

There were a total of 12 studies provided the OS data at 3 years, and 10 studies at 5 years. Results showed that TPX2 expression increased in tumor tissue had a negative effect to 3-year OS (OR = 4.63, 95% CI: 3.27--6.56, *P* \< .00001), and 5-year OS (OR = 4.05, 95% CI: 2.32--7.07, *P* \< .00001) (Fig. [2](#F2){ref-type="fig"}). Similarly, 4 studies reported survival data for both 3 and 5-year DFS, results showed that elevated TPX2 expression was also related with obviously poor 3-year DFS (OR = 3.35, 95% CI: 1.83--6.14, *P* \< .0001), and 5-year DFS (OR = 2.94, 95% CI: 1.74--4.98, *P* \< .0001) of solid cancers (Fig. [3](#F3){ref-type="fig"}). There was low or moderate heterogeneity of the data among studies. Thus, we performed subgroup meta-analysis to figure out whether the various cancer types lead to the heterogeneity.
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In the following analysis of subgroups classified by different cancer types, we discovered that TPX2 expression was related to the worse 3-year OS of gastric cancer (n = 2, OR = 10.63, 95% CI: 3.41--33.15, *P* \< .0001) (Fig. [4](#F4){ref-type="fig"}A), esophageal squamous cell cancer (n = 2, OR = 2.58, 95% CI: 1.06--6.28, *P* = .04) (Fig. [4](#F4){ref-type="fig"}B), and hepatocellular cancer (n = 2, OR = 4.74, 95% CI = 1.68--13.39, *P* = .003) (Fig. [4](#F4){ref-type="fig"}C). Consistent with the results above, TPX2 expression was related to the worse 5-year OS of hepatocellular cancer (n = 2, OR = 4.25, 95% CI: 2.36--7.67, *P* \< .00001) (Fig. [4](#F4){ref-type="fig"}E). Also, we found TPX2 expression had a negative relationship with 3-year DFS of esophageal squamous cell cancer (n = 2, OR = 3.72, 95% CI: 1.36--10.14, *P* = .01) (Fig. [5](#F5){ref-type="fig"}A) and hepatocellular cancer (n = 2, OR = 4.09, 95% CI: 1.06--15.80, *P* = .04) (Fig. [5](#F5){ref-type="fig"}B), and with 5-year DFS of hepatocellular cancer (n = 2, OR = 4.13, 95% CI = 1.34--12.73, *P* = .01) (Fig. [5](#F5){ref-type="fig"}D). However, significant relationship between TPX2 expression and 5-year OS/DFS of esophageal squamous cell carcinoma was not found (both *P* = .05) (Figs. [4](#F4){ref-type="fig"}D and [5](#F5){ref-type="fig"}C).

![Subgroup analysis of overall survival (OS) at 3 and 5 years by the expression level of TPX2 in different cancer types. A, Gastric cancer and 3-year OS. B, Esophageal squamous cell cancer and 3-year OS. C, Hepatocellular cancer and 3-year OS. D, Esophageal squamous cell cancer and 5-year OS. E, Hepatocellular cancer and 5-year OS. CI = confidence interval, TPX2 = targeting protein for Xklp2.](medi-97-e13018-g006){#F4}

![Subgroup analysis of disease-free survival (DFS) at 3 and 5 years by the expression level of TPX2 in different cancer types. A, Esophageal squamous cell cancer and 3-year overall survival (OS). B, Hepatocellular cancer and 3-year OS. C, Esophageal squamous cell cancer and 5-year OS. D, Hepatocellular cancer and 5-year OS. CI = confidence interval, TPX2 = targeting protein for Xklp2.](medi-97-e13018-g007){#F5}

3.4. Sensitivity analyses
-------------------------

Removing the researches with NOS score \<7 did not affect results for OS at 3 or 5 years (OR = 4.93, 95% CI: 3.35--7.24, *P* \< .00001; OR = 4.63, 95% CI: 3.19--6.74, *P* \< .00001, respectively), and did not affect results for DFS at 3 or 5 years (OR = 3.88, 95% CI: 1.85--8.15, *P* = .0003; OR = 3.16, 95% CI: 1.65--6.05, *P* = .0005, respectively) as well. Elimination of these studies did not reduce heterogeneity for 3-year OS, 3-year DFS, or 5-year DFS (Cochran Q *P* = .14, *I*^2^ = 34%; Cochran *Q P* = .08, *I*^2^ = 56%; Cochran *Q P* = .15, *I*^2^ = 43%, respectively), but reduce heterogeneity for 5-year OS (Cochran *Q P* = .23, *I*^2^ = 24%).

Removing the studies that TPX2 expression was not detected by IHC did not affect results for OS at 3 or 5 years (OR = 4.91, 95% CI: 3.43--7.04, *P* \< .00001; OR = 4.90, 95% CI: 3.41--7.04, *P* \< .00001, respectively), and did not affect results for DFS at 3 or 5 years (OR = 3.31, 95% CI: 1.70--6.46, *P* = .0004; OR = 2.99, 95% CI: 1.63--5.49, *P* = .0004, respectively) as well. Exclusion of these studies did not reduce heterogeneity for 3-year OS, 3-year DFS or 5-year DFS (Cochran *Q P* = .13, *I*^2^ = 34%; Cochran *Q P* = .05, *I*^2^ = 62%; Cochran *Q P* = .14, *I*^2^ = 46%, respectively), but reduce heterogeneity for 5-year OS (Cochran *Q P* = .21, *I*^2^ = 27%).

3.5. Publication bias
---------------------

Funnel plot analysis was performed to estimate the potential bias in the included publications, and results revealed that there was no significant publication bias for OS and DFS in our meta-analysis (Fig. [6](#F6){ref-type="fig"}).

![A, Publication bias funnel plot of the studies assessing targeting protein for Xklp2 (TPX2) expression and 3-year overall survival in solid tumors. B, Publication bias funnel plot of the studies assessing TPX2 expression and 5-year overall survival in solid tumors. C, Publication bias funnel plot of the studies assessing TPX2 expression and 3-year disease-free survival in solid tumors. D, Publication bias funnel plot of the studies assessing TPX2 expression and 5-year disease-free survival in solid tumors. Visual inspection of the funnel plot did not identify substantial asymmetry.](medi-97-e13018-g008){#F6}

4. Discussion
=============

The initiation and progression of tumors is a complex process with many factors may make a contribution, among them is the dysfunction of MT.^\[[@R34]\]^ TPX2 is a kind of MAP controls MT function and dynamics, and therefore may play an important role in the development of tumors.

Recently, a systematic review containing 10 studies with 906 patients was carried out by Gang et al. Results showed that TPX2 was overexpression in most digestive system tumors and their expression status was associated with obviously worse survival rate.^\[[@R35]\]^ In addition to digestive system tumors, TPX2 overexpression also exists in many other kinds of malignant neoplasms. Most studies suggest that enhanced expression of TPX2 in tumor tissue worsens the clinical outcome and decreasing TPX2 levels may be a beneficial approach for cancer treatment. For instance, Yan et al found that transfection of TPX2 siRNA decreased the viability and proliferation capacity of bladder carcinoma cell lines and TPX2-depleted tumor cells obviously grew more slowly in nude mice.^\[[@R25]\]^ However, Pan et al suggested that the TPX2 expression level was not significantly different in relation to cumulative survival in human prostate cancer patients.^\[[@R30]\]^ In light of the significant role of TPX2 in clinical application, we performed this meta-analysis to evaluate the relationship between TPX2 expression and prognosis of patients with various solid tumors.

In this systematic analysis, we pooled and evaluated survival data from 13 studies, which including 2134 patients, and demonstrated that the elevated expression of TPX2 was a prognostic marker of unfavorable clinical outcome, with consistent results of OS or DFS at 3 and 5 years. In the subgroup analysis stratified by tumor types, elevated TPX2 expression was associated with unfavorable 3- and 5-year OS/DFS of hepatocellular cancer and gastric cancer. And though overexpression of TPX2 was related to worse 3-year OS/DFS of esophageal squamous cell cancer, no significant relationship between TPX2 expression and 5-year OS/DFS of esophageal squamous cell cancer was found. Moreover, 1 study showed that TPX2 overexpression in prostate cancer tissues was associated with preferable 5-year OS. As far as we know, TPX2 is a protein with several functional regions. Its N-terminus directly binds to and activated Aurora A kinase, which is a potential cancer marker important for cell proliferation.^\[[@R36]\]^ And its C-terminus binds to Eg5 and Xblp2 kinesin (named "targeting protein for Xklp2" for that reason), mediating these motors' spindle localization.^\[[@R3],[@R37]\]^ Except for these, unfortunately, we know little about the molecular mechanism and function of TPX2 in cancer pathogenesis, and cannot explain why TPX2 plays a catalytic role in some tumors, but not in others. These discrepancies suggest further attention should be paid to discover how TPX2 works at the cellular and molecular levels.

What is novel about this research is that it is the first systematic evaluation of the literatures with respect to TPX2 expression and clinical outcomes in patients with various solid tumors. This research also involves several meaningful implications. Firstly, it shows that in most solid tumors, TPX2 overexpression is correlated with unfavorable outcomes. Thus, along with imaging technology and other tumor biomarkers,^\[[@R38]--[@R40]\]^ TPX2 may play an essential role in assessing the prognosis of various neoplasms. Secondly, by subgroup analysis, TPX2 expression presents negative relation with outcomes in gastric cancer and hepatocellular cancer, but irrelevant to long-term outcome in esophageal squamous cell cancer, which indicated that the function of TPX2 may be heterogeneous in different tumors.

There are also several limitations presented in our meta-analysis. First, some survival data were extracted from Kaplan-Meier curves artificially; thus, slight deviations may exist, although they could hardly influence the analysis results. Second, the detection methods and cut-off values of TPX2 expression are nonuniform in different articles. Third, stratification analysis for most types of tumor failed to be performed, because there were not enough date so far. Lastly, most researches included in our meta-analysis were performed in China. Thus, no firm conclusions can be drawn in other kinds of people and the differences between human races are uncertain. Further studies need to be performed to confirm the impact of human species on the results of studies.

In conclusion, our meta-analysis demonstrates that TPX2 overexpression is related to unfavorable outcome in most solid tumors, implying that TPX2 is a potential prognostic marker and therapeutic target for various solid tumors.
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